Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07132515
Recruiting Phase 4

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

NCT07132515 · tracked via the Priya Life Science Egypt tracker
Sponsor
Mansoura University
Phase
Phase 4
Started
2023-08-15
Last updated
2025-08-20

Condition(s) studied

CirrhosisHCC - Hepatocellular CarcinomaPortal Vein Thrombosis

Investigational drug(s) / intervention(s)

Enoxaparin, warfarrin, or apixaban →

Enoxaparin, warfarrin, or apixaban: Enoxaparin, warfarrin, or apixaban

Study summary

We will give an anticoagulant against portal vein thrombosis, and watch for the results.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B Exclusion Criteria: * Platelets\<10000, Createnine \>1.9, Budd ciarri, Uncontrolled active bleeding

Primary outcome measure(s)

  • Portal vein thrombosis — 6 months
    determine if thrombus resolved or not on anticcoagulant by triphasic CT

Trial sites (1)

FacilityCityRegionStatus
Mansoura University Hospitals Al Mansurah Dakahlia Governorate Recruiting

More Mansoura University trials in Egypt

PCNL Versus RIRS for Management of Stones in Solitary Kidney Active, not recruiting
Role of HFNC During FOB in Patients With Respiratory Failure Recruiting
FANS-FURS vs Suction Mini-PCNL for 2-3 cm Renal Stones: A Multicenter Randomized Trial Starting soon
Fully Versus Partially Guided Implants Placement: Measurement of Accuracy of Implant Position and Passivity of Superstructures. Active, not recruiting
Maxillary and Mandibular Nerve Block Recruiting

Other trials for the same condition

Real-world Insight Into Systemic Therapies for HCC: Single-center Study Recruiting
Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals Enrolling by invitation
Predictors of HCC in Post-HCV Cirrhotic Patients After SVR Starting soon
Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients Recruiting
Portal Vein Thrombosis in Liver Cirrhosis: Clinical Characteristics, Radiological Patterns, and Predictors Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07132515 on ClinicalTrials.gov ↗ ← All trials in Egypt